Brief: Orchard Therapeutics U.S. FDA Accepted Filing Of BLA For Otl-200 In Metachromatic Leukodystrophy Under Priority Review
18/09/2023 12:36
Sept 18 (Reuters) - Orchard Therapeutics PLC OT10y.F :
* U.S. FDA ACCEPTED FILING OF BLA FOR OTL-200 IN
METACHROMATIC
LEUKODYSTROPHY UNDER PRIORITY REVIEW
* AGENCY HAS SET A PDUFA GOAL DATE OF MARCH 18, 2024
Source text: [ID:https://bit.ly/45WArFK]
Further company coverage: OT10y.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orchard Therapeutics
See all newsBrief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln